FORTIS-M: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients with Non-Small Cell Lung Cnacer who have failed Two or More Prior Treatment Regimens
|Effective start/end date||10/20/09 → 6/27/10|
- IQVIA, INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.